Senti Biosciences, Inc. (SNTI)
NASDAQ: SNTI · Real-Time Price · USD
0.9303
+0.1081 (13.15%)
At close: Feb 6, 2026, 4:00 PM EST
0.9060
-0.0243 (-2.61%)
Pre-market: Feb 9, 2026, 5:53 AM EST
Senti Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
34
Market Cap
24.46M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 2.56M | -1.73M | -40.25% |
| Dec 31, 2022 | 4.29M | 1.53M | 55.23% |
| Dec 31, 2021 | 2.76M | 2.20M | 387.81% |
| Dec 31, 2020 | 566.00K | 481.00K | 565.88% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IGC Pharma | 1.11M |
| Rallybio | 674.00K |
| Exicure | 500.00K |
| Serina Therapeutics | 116.00K |
| Daré Bioscience | -57.13K |
SNTI News
- 5 days ago - Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026 - GlobeNewsWire
- 25 days ago - Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation - GlobeNewsWire
- 4 weeks ago - Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Senti Biosciences Announces New Employment Inducement Grants - GlobeNewsWire
- 2 months ago - Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia - GlobeNewsWire
- 2 months ago - Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile - GlobeNewsWire
- 2 months ago - Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET - GlobeNewsWire
- 3 months ago - Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December - GlobeNewsWire